Compare Altria Group Inc (MO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TransMedics Group Inc — how do they compare? Altria Group Inc trades at $71.26 (market cap $115.85B), while TransMedics Group Inc trades at $79.33 (market cap $2.81B). The key difference: Altria Group Inc is far larger — about 41.2× TransMedics Group Inc's market cap, and Altria Group Inc pays a 6.4% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and TransMedics Group Inc for 24 Days on average.
| MO | TMDX | |
|---|---|---|
Market Cap | $115.85B | $2.81B |
Volume | 6,934,962 | 962,415 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $150.42 |
52-Week Low | $54.72 | $61.99 |
Typical Hold Time | 154 Days | 24 Days |
Enterprise Value | $138.06B | $3.21B |
Dividend Yield | 6.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.43, up 4.2% today, showing strong momentum despite mixed earnings history with two misses and one beat in recent quarters. The stock maintains a 6.6% dividend yield with 60 consecutive annual increases, supported by robust cash flow generation. Technical indicators show a bullish trend with current price near resistance at $71, while fundamentals reveal stable revenue around $20B annually but declining profit margins from 55.1% in 2024 to 34.5% in 2025.
MO presents a high-yield opportunity with strong cash flows but faces significant headwinds including negative shareholder equity, regulatory pressures, and declining cigarette volumes. Analyst consensus remains positive with 62% buy ratings and $69.71 price target, though the stock trades slightly above this target. The company's transition to smoke-free products remains critical for long-term sustainability amid changing consumer preferences.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
